A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease.

@article{Loeb2004ARC,
  title={A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease.},
  author={Mark Loeb and D. William Molloy and Marek Smieja and Tim Standish and Charlie H. Goldsmith and James B. Mahony and Stephanie L. Maatta Smith and Michael Borrie and Earl Decoteau and Warren Davidson and Allan McDougall and Judy Gnarpe and MARTIN W. O'DONNELL and Max A Chernesky},
  journal={Journal of the American Geriatrics Society},
  year={2004},
  volume={52 3},
  pages={381-7}
}
OBJECTIVES To assess whether doxycycline and rifampin have a therapeutic role in patients with Alzheimer's disease (AD). DESIGN Randomized, triple-blind, controlled trial. SETTING Three tertiary care and two community geriatric clinics in Canada. PARTICIPANTS One hundred one patients with probable AD and mild to moderate dementia. INTERVENTION Oral daily doses of doxycycline 200 mg and rifampin 300 mg for 3 months. MEASUREMENTS The primary outcome was a change in Standardized… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice.

Drug metabolism and disposition: the biological fate of chemicals • 2015
View 3 Excerpts
Highly Influenced

Chlamydia pneumoniae: An Etiologic Agent for Late-Onset Dementia

Front. Aging Neurosci. • 2018
View 3 Excerpts
Highly Influenced

P-glycoprotein (ABCB1) and Oxidative Stress: Focus on Alzheimer's Disease

Oxidative medicine and cellular longevity • 2017
View 3 Excerpts
Highly Influenced

Can oral infection be a risk factor for Alzheimer's disease?

Journal of oral microbiology • 2015
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…